Drugs / Fucoxanthin
Fucoxanthin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03613740 | Sep 2019 → Jan 2022 | metabolic syndrome X | University of Guadalajara | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fucoxanthin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03613740 ↗ |
| Known as | All-trans-fucoxanthin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773903 ↗ |
| Known as | CHEBI:5186 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773903 ↗ |
| Known as | Fucoxanthin, all-trans- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773903 ↗ |
| Known as | Sebatrol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1773903 ↗ |
| Modality | Small molecule | “Fucoxanthin, one of the most abundant carotenoids from edible brown seaweeds, for years has been used as a bioactive dietary supplement and functional food ingredient.” PMID 33993853 ↗ May 2021 |
| Route | Oral | “Patients will receive a capsule with Fucoxanthin 12 mg or homologated placebo once a day during 90 days.” NCT03613740 ↗ |